Characterizing the Pharmacokinetics of High Dose Rifampicin and Linezolid in a Randomized Controlled Trial for HIV-associated Tuberculous Meningitis
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Funding Fogarty Program
Emerging Global Leader
Project Information in NIH RePORTER
Characterizing the Pharmacokinetics of High Dose Rifampicin and Linezolid in a Randomized Controlled Trial for HIV-associated Tuberculous Meningitis
Principal Institution
University of Cape Town
Principal Investigator(s) (PI)
Wasserman, Sean Adam
Project Contact Information
Email: sean.wasserman@uct.ac.za
Year(s) Awarded
2019-2023
Country
South Africa
Project Description
Tuberculous meningitis (TBM) is the most serious form of tuberculosis, requiring novel therapeutic approaches to improve outcomes. The project will leverage a Phase 2a clinical trial of intensified antimicrobial therapy for HIV-associated TBM in South Africa to characterize the pharmacokinetics of high dose rifampicin and linezolid, with the objective of informing dose optimization for efficacy trials and clinical practice.
Related World Regions / Countries
Related Global Health Research Topics